Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
In December 2020, the FDA approved Xpovio (selinexor), for use in combination with the proteasome inhibitor Velcade (bortezomib) and the steroid dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous therapy. Xpovio was previously approved for several types of lymphoma.
FDA Approvals, News & UpdatesMultiple Myeloma
Adrug called Blenrep (belantamab mafodotin-blmf) was recently approved by the Food and Drug Administration (FDA) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies (including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent).
Multiple Myeloma
Here are the drugs and financial support services available to patients receiving treatment for Multiple Myeloma.
FDA Approvals, News & UpdatesMultiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Multiple Myeloma
How data collected from patients in routine
clinical practice are driving improvements
in the management of multiple myeloma
Multiple Myeloma
By Jack AielloJack Aiello, Deborah Christensen, MSN, APRN, AOCNS, HNB-BCJack Aiello, Deborah Christensen, MSN, APRN, AOCNS, HNB-BC, Lori Puente
No one is ready for the initial shock that comes with a diagnosis of cancer. The feelings that accompany a cancer diagnosis may be difficult to imagine beforehand, challenging to process as you hear and attempt to accept the news, and impossible to appreciate fully if you are not the individual who has just been diagnosed.
Multiple Myeloma
When you are first diagnosed with cancer, including multiple myeloma, you probably have many questions. You may ask: Do I have a multiple myeloma specialist close to my home? If not, am I able to travel? Should I consider participating in a clinical trial if I am eligible and my doctor recommends it?